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ABSTRACT
Background: Clozapine is the only drug approved for treatment-resistant schizophrenia. There is evi-
dence that clozapine is underutilized. Aims: To evaluate the initiation and discontinuation of clozapine
at Landspitali University Hospital in Iceland and the prevalence of antipsychotic polypharmacy in cloza-
pine-treated patients. Methods: The study is a part of an ongoing longitudinal study of schizophrenia
in Iceland. We identified 201 patients on clozapine or who have been on clozapine by using a keyword
search in the electronic health records and by reviewing their medical records. Results: Mean age at
first treatment with clozapine was 37.8 years. Mean follow-up period on clozapine was 11 years. After
20 years of treatment 71.2% of patients were still on clozapine. After one year of treatment 84.4% of
patients were still receiving clozapine treatment. We estimate that 11.4% of patients with schizophrenia
in Iceland are taking clozapine and that 16% have been treated with clozapine at some point.
Polypharmacy is common, since nearly 2/3, 65.6%, of patients taking clozapine use at least one other
antipsychotic and 16.9% are also receiving depot injections. Conclusions: We need to increase the
awareness of psychiatrists in Iceland with regard to treatment with clozapine, since only about half of
the estimated population of patients with treatment-resistant schizophrenia in Iceland have ever been
treated with clozapine. Nearly two thirds of patients who are prescribed clozapine in Iceland remain on
it long-term.
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Around 20–30% of patients with schizophrenia prove to be
treatment-resistant, and clozapine has been demonstrated to
be the drug of choice to offer those patients (1). Treatment
resistance has been defined as failure to respond to two or
more antipsychotics (one of which should be an atypical)
when given at an adequate dose for at least 6–8 weeks
(2,3). Clozapine has also been found to be superior to other
antipsychotic medications for non-treatment-resistant schizo-
phrenia in a meta-analysis (4). In addition to having an indi-
cation for treatment-resistant schizophrenia, clozapine also
has FDA approval for the prevention of recurrent suicidal
behaviour, its effectiveness in this indication having been
demonstrated in the international suicide prevention trial
(InterSePT) (5).
There is evidence that clozapine remains underutilized
despite being the only drug approved for treatment-resistant
schizophrenia (6,7). Clozapine use in schizophrenia varies
widely between countries: from being as high as 26.9% (8) in
Taiwan, 26.7% in China (8), 15.2% in Australia (9), 10.1% in
Denmark (10), to as low as 4.4% in the USA (11). It is not well
understood why clozapine appears underutilized in some
countries despite the strong evidence for its efficacy in treat-
ment-resistant schizophrenia. Possible explanations include
the strict haematological monitoring requirements and the
potential for rare but potentially serious side effects such as
agranulocytosis, myocarditis and seizures, and more common
ones such as weight gain and type 2 diabetes mellitus.
Clozapine has been established as a cost effective treat-
ment for treatment-resistant schizophrenia. Patients on cloza-
pine have reduced frequency of hospital admissions (12).
Schizophrenia is a disorder known in all settings and cultures.
The prevalence of schizophrenia is more geographically var-
ied than previously assumed, but it is estimated that 7 indi-
viduals per 1000 will be affected, but gender, urbanity,
latitude and migration have been shown to influence inci-
dence rates (13,14).
Aims of the study
The aim of the study is to describe clozapine treatment of
patients with schizophrenia in Iceland; specifically to describe
the proportion of patients taking clozapine, the pattern of dis-
continuation over time and the frequency of antipsychotic
polypharmacy in patients treated with clozapine.
Materials and methods
Landspitali University Hospital (LUH) started to use electronic
health records (EHR) in 1998, but older records are available
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on paper. Subsequently the proportion of medical, psych-
ology and nursing data in EHR has been steadily growing and
currently includes almost all patient data in the hospital.
This study constitutes a part of an ongoing longitudinal
study in the LUH department of psychiatry focusing on
patients with schizophrenia and bipolar disorder. Patients
have been recruited to the study in several waves from
1986–2014. The majority of inpatients and outpatients at LUH
with schizophrenia or bipolar disorder have been approached
to take part in the study. Most of the patients were recruited
between the years 2000 and 2004. In this study we looked
at patients from the LUH study who were alive on 1 January
2003 and had a confirmed diagnosis of schizophrenia
according to the Schedule for Affective Disorder and
Schizophrenia – Lifetime version (SADS-L) (15). In total 611
patients met the inclusion criteria.
LUH is the only tertiary hospital for mental health services
in Iceland and it also provides secondary psychiatric services
and inpatient beds in psychiatry for over 90% of the Icelandic
population. Therefore the overwhelming majority of Icelandic
patients with treatment-resistant schizophrenia who have
ever been on clozapine have been in regular or temporary
contact with the mental health services or other services of
LUH.
To identify patients that have used clozapine we used a
keyword search in the EHR for the text ‘‘clozapin’’, ‘‘closapin’’
and ‘‘Leponex’’. The ‘‘e’’ at the end of clozapin was omitted
because of possible spelling errors in the EHR, but a keyword
search of ‘‘clozapin’’ will find ‘‘clozapin’’ and ‘‘clozapine’’. ‘‘clo-
sapin’’ with an ‘‘s’’ was also used in the keyword search.
Leponex was the only brand name of clozapine in Iceland
until May 2014 when the generic ‘‘Clozapine Actavis’’ was
introduced to the market. All medical notes with the cloza-
pine keywords were reviewed to assess whether clozapine
had been used. For patients who had insufficient documenta-
tion of prior psychiatric illness and medical use in the EHR
the paper medical records were reviewed for clozapine use.
The time period of clozapine use was documented. We identi-
fied 201 patients with schizophrenia and 23 patients with
bipolar disorder who had used clozapine.
Information on the first period of clozapine treatment for
patients with schizophrenia was available for 195 patients out
of 201. We had the exact date of clozapine initiation for 167
patients. For 28 patients it was not possible to set an exact
date for the initiation of clozapine treatment but from med-
ical records it was possible estimate the time from a couple
of weeks to a couple of months. Of those 28 patients, 24
patients started clozapine before 1998 which is when LUH
started using EHR.
When assessing the proportion of patients continuing on
clozapine we used a Kaplan–Meyer survival analysis. If a
patient had tried clozapine, then stopped clozapine and then
restarted then the start of clozapine treatment was defined
from the last start of clozapine treatment. Patients who
died during follow-up or were still taking clozapine at the
end of follow-up were censored from time of death or end of
follow-up.
In the ‘‘ever discontinued clozapine’’ analyses we exam-
ined the time from the first treatment with clozapine until
the patient discontinued clozapine treatment regardless of
whether they later restarted clozapine treatment.
When analysing concomitant medication use while
patients were taking clozapine we considered the last known
medication regime stated in the medical notes before the
end of follow-up or the date that the patient discontinued. It
may take up to 6 months of clozapine treatment to observe
full improvement in positive symptoms (11). Dosing adjust-
ment of clozapine therefore can take even longer so patients
had to have been on clozapine for at least 1 year to be
included. There was no minimum dose of clozapine so
patients using low doses of clozapine were also included. In
total we had detailed medication information for 154 patients
with schizophrenia and 145 out of them used 100mg of clo-
zapine or more.
We used the mean clozapine dose prescribed in the cohort
and the total clozapine sales in 2013 to estimate how many
patients with schizophrenia in Iceland had used clozapine
that year, assuming that the use of clozapine for disorders
other than schizophrenia and bipolar disorder was negligible.
Data used to assess antipsychotic drug use in Iceland in
2013 was collected from the Icelandic Medicines Agency.
The study was reviewed and approved by the Icelandic
National Bioethics Committee (FS-02-041(03–030)) and the
Data Protection Authority (2009090737þS).
Results
Age at first treatment with clozapine
The mean age at first treatment with clozapine was 37.8 years
(SD 12.2), 36.5 years (SD 12.5) for men and 41.0 years (SD 11)
for women. On average men started clozapine treatment 4.5
years earlier than women (p¼ 0.008).
Figure 1 describes the age of patients when clozapine
treatment was first started. The mean was 37.8 (SD 12.2) with
a range of 16.4–69.6 years.
The mean follow-up time on clozapine was 11.1 (SD 9)
years for men and 10.9 (SD 8.5) years for women.
Discontinuation of clozapine
Figure 2 is a Kaplan–Meier survival graph that displays the
proportion of patients that were on clozapine for the first 20
years of treatment. After 1 year of treatment 84.4% of
patients were still on clozapine and after 2 years 81.8% of
patients were still on clozapine. After a 20-year follow-up
71.2% of patients were still on clozapine, 71.5% of the men
and 70.1% of the women.
We also estimated with a Kaplan–Meier survival estimate
the proportion of patients who had ever discontinued cloza-
pine treatment after the first start of clozapine treatment with
a Kaplan – Meier survival estimate. One year after the first
start of clozapine treatment 17.6% of patients had discontin-
ued clozapine treatment, and 2 years after the start of cloza-
pine treatment 22.7% of patients had discontinued clozapine
treatment. Eighteen patients restarted clozapine treatment
after having discontinued clozapine use and 14 of them were
still on clozapine at the end of follow-up or when they died.
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Most patients who come off clozapine do so early on. In
the first 6 months 33 patients out of those 68 who ever dis-
continued it (48.5%) came off clozapine, three had died and
one was censored because of a follow-up time of less than
1 year. Two years after the first start of clozapine treatment
49 patients had stopped clozapine treatment (72% of total
discontinuation), four had died and two were censored.
Clozapine discontinuation did continue to occur at a slower
rate though during subsequent years of treatment.
Clozapine dosing and concomitant treatments
The mean dose of clozapine was 304.6mg (SD 172mg) and
the median dose was 262.5mg, range 25–800mg.
Table 1 describes polypharmacy in the cohort. About a third
of the patients received clozapine as their only antipsychotic.
About two thirds of patients (65.5%) were prescribed more
than one antipsychotic. The average World Health
Organization defined daily dose (DDD) of antipsychotics was
1.67 in the cohort (16). As the number of regular antipsychotic
drugs increased, the DDD also increased. The average DDD:
antipsychotic usage for patients whose sole antipsychotic was
clozapine was 1.01. For patients on four or more antipsychotics
the average DDD: antipsychotic usage was 3.01.
When analysing polypharmacy in the cohort we found 16
different antipsychotic drugs used with clozapine.
Chlorpromazine was the most commonly used antipsychotic
in oral preparations in addition to clozapine treatment, with
16 patients (10.4%) receiving chlorpromazine with clozapine.
Figure 1. Age of patients when clozapine treatment was first used (n¼ 195).
Figure 2. Proportion of patients who stay on clozapine after the latest start of clozapine treatment (n¼ 201).
Table 1. Antipsychotic polypharmacy (N¼ 154).
Daily antipsychotic use N % Mean DDD
Clozapine only 53 34.4 1.01
Clozapine plus one additional antipsychotic 70 45.5 1.79
Clozapine plus two additional antipsychotics 23 14.9 2.37
Clozapine plus three additional antipsychotics 8 5.2 3.01
1.67
DDD, defined daily dose by the World Health Organization.
452 O. INGIMARSSON ET AL.
D
ow
nl
oa
de
d 
by
 [G
ed
de
ild
 L
an
ds
pit
ali
] a
t 0
7:2
1 0
4 A
ug
us
t 2
01
6 
Table 2 describes the depot injections used with clozapine;
6.5% of all patients receiving clozapine also received perphe-
nazine depot injections and 5.8% received risperidone depot
injections. In total there were 26 patients out of 154 (16.9%)
that received depot antipsychotics alongside their clozapine
tablets. **One patient received two depot injections with
clozapine.
Regular use of benzodiazepine drugs (anatomical thera-
peutic chemical codes NO3AE** and N05BA**) was common
in the cohort but 69 patients out of 154 (44.8%) used them
daily. The average age of patients on benzodiazepine drugs
was 53.8 years and the average age for patients not using
benzodiazepine drugs daily was 50.0 years. Clonazepam was
the most commonly used benzodiazepine; 45 patients out of
154 (29.2%) used it daily. Antidepressants use was also com-
mon with 74 patients out of 154 (48.1%) using antidepres-
sants daily, sertraline being the most common antidepressant
(16.2%).
Antipsychotic sales in Iceland
Table 3 describes antipsychotic sales figures in Iceland in
2013. Clozapine was the fifth most common antipsychotic in
Iceland with 224 DDD: sold per day and a market share of
6.2%.
The average clozapine dose in the group of patients with
schizophrenia was 304.6mg. There were 23 patients out of
224 (10.3%) with SADS-L confirmed bipolar disorder who had
used clozapine. The average dose of clozapine for those with
bipolar disorder was 215.8mg (SD 150) and the median dose
was 200mg, range 50–500mg.
We estimated that patients with schizophrenia used
92.7% of the clozapine prescribed, and patients with bipolar
disorder used around 7.3% of total clozapine sold (23/
224) (215.8mg/304.6mg). The total population in Iceland
at the end of 2013 was 325,671 and the population aged
15 years and older was 255,391 (17). We used the preva-
lence of schizophrenia as 0.7% (13,14) and extrapolated that
for the population 15 years and older we could estimate
that there were 1,788 (0.7%  255.391) patients with schizo-
phrenia in Iceland in 2013. Total mg of clozapine sold in
2013 in Iceland was 24,524,967mg. We estimated that the
total amount of clozapine sold for schizophrenia was
22,734,644mg (92.7%  24,524,967mg). Dividing the total
amount of clozapine sold with the mean dose used in
schizophrenia in Iceland gave us an estimated number of
total patients using clozapine in 2013 as 204 (22,734,644)/
(304.6 365 days). We know that 71.2% of patients stay on
clozapine so using that percentage we estimated the
number of patients with schizophrenia that had ever used
clozapine in 2013 to be 287 (204/71.2%). We therefore esti-
mated the proportion of patients with schizophrenia in
Iceland using clozapine in 2013 to be 11.4% (204/1.788) and
the proportion of patients with schizophrenia that have ever
used clozapine to be 16% (204)/(1.788 71.2%).
Discussion
The proportion of patients that remained on clozapine during
20 years of follow-up in the study proved to be very high, or
71.2%. In view of the multiple side effects of clozapine, this
high proportion appears to indicate that clozapine is an
effective drug for patients with treatment-resistant schizo-
phrenia in our cohort. The high proportion may also reflect to
a degree the fact that there are no other available drugs indi-
cated for treatment-resistant schizophrenia. One year after
starting clozapine treatment 84.4% of patients remained on
clozapine, which is higher than in a study by Essock et al.
where 74% of patients were still taking clozapine after 1 year
of treatment (18). Two years after starting treatment the pro-
portion still taking clozapine was 81.8% which is higher than
in the study by Essock et al. where it was 66%. In a naturalis-
tic Chinese study which compared the discontinuation rate of
clozapine to other antipsychotics 1 year after starting treat-
ment in early stage schizophrenia, 62.3% of patients remained
on clozapine (19). We can only speculate why the proportion
is even higher in Iceland. This may be the result of several
factors: most patients start on clozapine as inpatients, the
mean dose of clozapine is fairly low, it is often prescribed
only in the evening to reduce daytime sedation, blood moni-
toring is less stringent than in some countries such as the UK
and the USA, and finally, continuity of care is probably overall
more common than in larger societies.
In the clozapine phase of the CATIE trial the time to dis-
continuation was significantly longer for clozapine than for
other antipsychotics. Despite the treatment resistance require-
ment and the multiple side effects many patients experience
on clozapine treatment, patients with schizophrenia tend to
stay on it longer than on other antipsychotics (20).
The mean clozapine dose of 304mg a day used in our
sample is a similar to the average dose of 284mg in Europe
as reported by Fleischhacker and colleagues (21). The same
study reported a higher mean clozapine dose in the USA of
444mg daily. In a recent study by Nielsen and colleagues the
mean clozapine dose in a Danish cohort was reported to be
382mg (10). In a small Swedish cohort (n¼ 33) the clozapine
Table 2. Depot injection used for patients on clozapine (N¼ 154).
n % Mean daily dose* (mg) DDD (mg)
Perphenazine 10 6.5 7.3 7
Risperidone 9 5.8 3.4 2.7
Zuclopenthixol 4 2.6 14.3 15
Flupentixol 3 1.9 1.9 4
Olanzapine 1 0.6 21.4 10
26** 16.9
*Mean daily dose is the depot injection dose divided by the number of days
between injections. DDD, defined daily dose by the World Health Organization.
Table 3. Antipsychotics sold in Iceland in 2013.
Drug name DDD (mg)
Total DDD
in 2013 Total DDD/day
Proportion of
total sales (%)
Quetiapine 400 339.981 931 26.0
Olanzapine 10 325.269 891 24.9
Risperidone 5 159.052 436 12.2
Aripiprazole 15 95.152 261 7.3
Clozapine 300 81.750 224 6.2
Perphenazine 30 72.593 199 5.5
Other antipsychotics – 241.672 662 17.9
3604
DDD, defined daily dose by the World Health Organization.
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dose was recently reported to be somewhat higher at
460mg, and closer to doses seen in the USA (22).
Polypharmacy was common in our cohort, with 65.6% of
patients using clozapine and at least one another anti-
psychotic, which was about the same percentage as recently
reported in the Danish cohort, 64.2% (10). There is, though,
little evidence to support such widespread antipsychotic poly-
pharmacy in schizophrenia treatment, as was observed in the
cohort (23).
The proportion of patients defined as treatment-resistant
has been estimated in the range of 20–30% (1). We estimate
that 16% of all patients with schizophrenia in Iceland have at
some point been treated with clozapine. This is somewhat
lower than the estimated proportion of patients with treat-
ment-resistant schizophrenia. This suggests that psychiatrists
need to be more alert in considering clozapine as an option
and address issues that might contribute to the low use of
clozapine.
Clinicians might overestimate the risk benefit ratio of
agranulocytosis and associated mortality versus the benefits
of treatment. Even though clozapine can very rarely cause
fatal agranulocytosis it has been shown that clozapine use
reduces total mortality of patients with schizophrenia (24)
and reduces the risk of suicide attempts (5). The risk of agran-
ulocytosis is estimated to be around 0.68% (25). Mortality in
agranulocytosis has been estimated to be about 2.7–3.1%
and therefore the absolute mortality of patients on clozapine
because of agranulocytosis is very low at around 0.02%
(25,26). Life expectancy in schizophrenia is reported to be
reduced by 22.5–25 years, which is about 40% of their total
adult years, due to poor physical health and a high suicide
rate (27). If we set the low risk of mortality due to agranulo-
cytosis in the context of increased survival by those on cloza-
pine and that living with schizophrenia reduces adult years
by about 40%, then the absolute mortality rate of 0.02% or
one in 5000 due to agranulocytosis seems clinically insignifi-
cant. We can also compare the mortality for agranulocytosis
to dying in an automobile accident in Iceland. The average
number of people dying annually in an automobile accident
in Iceland in 1995–2014 was 16.3 (28). The mean population
in Iceland in the years 1995–2014 was 296,004 (17). The risk
of dying in an automobile accident over a 40-year period is
estimated to be 0.22% (1 [(1 16.3/296,004)40]). We there-
fore estimate that it is 10 times more likely that a patient
with schizophrenia who is taking clozapine dies in an auto-
mobile accident in adulthood than from agranulocytosis.
Neutrophil monitoring for patients on clozapine has not been
shown to be cost effective, which reflects the very low mor-
tality of agranulocytosis (29). In light of the above we recom-
mend that the risk of agranulocytosis should not be the main
or the only decisive factor when clinicians assess whether
patients with treatment-resistant schizophrenia are offered
commencement of clozapine treatment.
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